CTLA4 and cancer: The SWOG S1609 Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) trial is a multicenter, prospective, open-label phase II study evaluating dual immune checkpoint inhibition with ipilimumab and nivolumab in rare cancers, including VSCC.